Stage 0 melanoma is defined by the American Joint Committee on Cancer's TNM classification system:Tis, N0, M0Patients with stage 0 disease may be treated by excision with minimal, but microscopically free, margins. Current Clinical TrialsCheck for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with stage 0 melanoma. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.General information about clinical trials is also available from the NCI Web site.References: Melanoma of the skin. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 325-44.
After nonmelanoma skin cancer has been diagnosed,tests are done to find out if cancer cells have spread within the skin or to other parts of the body. The process used to find out if cancer has spread within the skin or to other parts of the body is called staging. The information gathered from the staging process determines the stage of the disease. It is important to know the stage in order .
Following is a list of clinicopathologic cellular subtypes of malignant melanoma. These should be considered descriptive terms of historic interest only as they do not have independent prognostic or therapeutic significance. Superficial spreading.Nodular.Lentigo maligna.Acral lentiginous (palmar/plantar and subungual).Miscellaneous unusual types: Mucosal lentiginous (oral and genital).Desmoplastic.Verrucous.Molecular characterization of melanoma is an active area of research. Activating mutations in the BRAF (V-raf murine sarcoma viral oncogene homolog B1) gene, first reported in 2002, are the most frequent mutation in cutaneous melanoma. Approximately 40% to 60% of malignant melanomas harbor a single nucleotide transversion. The majority have a mutation that results in a substitution from valine to glutamic acid at position 600 BRAF (V600E); less frequent mutations include valine 600 to lysine or arginine residues (V600K/R). Drugs that target this mutation by inhibiting BRAF are
PDQ IS A COMPREHENSIVE CANCER DATABASE AVAILABLE ON NCI'S WEB SITE. PDQ is the National Cancer Institute's (NCI's) comprehensive cancer information database. Most of the information contained in PDQ is available online at NCI's Web site. PDQ is provided as a service of the NCI. The NCI is part of the National Institutes of Health,the federal government's focal point for biomedical research. .
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Skin Cancer Screening
Melanoma is a disease in which malignant (cancer) cells form in the skin cells called melanocytes (cells that color the skin). Melanocytes are found throughout the lower part of the epidermis. They produce melanin,the pigment that gives skin its natural color. When skin is exposed to the sun,melanocytes produce more pigment,causing the skin to tan,or darken. The skin is the body’s largest ..
Stage I melanoma is defined by the following clinical stage groupings: T1a,N0,M0 T1b,N0,M0 T2a,N0,M0 STANDARD TREATMENT OPTIONS: Current evidence suggests that lesions <2 mm thick may be treated conservatively with radial excision margins of 1 cm. A randomized trial compared narrow margins (1 cm) with wide margins (at least 3 cm) in patients with melanomas no thicker than 2 mm.[ 1,2 ] ...